ClinConnect ClinConnect Logo
Search / Trial NCT01850602

A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

Launched by KISSEI PHARMACEUTICAL CO., LTD. · May 8, 2013

Trial Information

Current as of July 22, 2025

Completed

Keywords

Hemodialysis Hyperphosphatemia

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients age 20 or older, regardless of gender.
  • Receiving stable maintenance hemodialysis 3 times a week.
  • Patients not having changed their phosphate binder agent dose, for 4 weeks or more before their observation period start.
  • Exclusion Criteria:
  • Patients having history of a pronounced brain / cardiovascular disorder.
  • Patients having severe gastrointestinal disorders.
  • Patients having severe hepatic disorders.

About Kissei Pharmaceutical Co., Ltd.

Kissei Pharmaceutical Co., Ltd. is a leading Japanese pharmaceutical company dedicated to the research, development, and commercialization of innovative therapies to address unmet medical needs. With a strong focus on specialty pharmaceuticals, Kissei leverages advanced technologies and rigorous clinical research to create effective treatments in areas such as urology, nephrology, and diabetes management. Committed to enhancing patient outcomes, Kissei collaborates with healthcare professionals and research institutions worldwide, ensuring a comprehensive approach to drug development that aligns with global health standards and regulatory requirements.

Locations

Multiple Locations, , Japan

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials